» Articles » PMID: 31481984

MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions

Overview
Journal Dis Markers
Publisher Wiley
Specialty Biochemistry
Date 2019 Sep 5
PMID 31481984
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant pleural mesothelioma (MPM) is an incurable cancer of the pleura that can be difficult to diagnose. Biomarkers for an easier and/or earlier diagnosis are needed. Approximately 90% of MPM patients develop a pleural effusion (PE). PEs are ideal sources of biomarkers as the fluid would almost always require drainage for diagnostic and/or therapeutic reasons. However, differentiating MPM PE from PE caused by other diseases can be challenging. MicroRNAs are popular biomarkers given their stable expression in tissue and fluid. MicroRNAs have been analysed in PE cytology samples for the diagnosis of MPM but have not been measured in frozen/fresh PE. We hypothesise that microRNAs expressed in PE are biomarkers for MPM. TaqMan OpenArray was used to analyse over 700 microRNAs in PE cells and supernatants from 26 MPMs and 21 other PE-causing diseases. In PE cells, combining miR-143, miR-210, and miR-200c could differentiate MPM with an area under the curve (AUC) of 0.92. The three-microRNA signature could also discriminate MPM from a further 40 adenocarcinomas with an AUC of 0.9887. These results suggest that the expression of miR-143, miR-210, and miR-200c in PE cells might provide a signature for diagnosing MPM.

Citing Articles

Optimal isolation of extracellular vesicles from pleural fluid and profiling of their microRNA cargo.

Chee T, OFarrell H, Lima L, Moller A, Fong K, Yang I J Extracell Biol. 2024; 2(10):e119.

PMID: 38939736 PMC: 11080846. DOI: 10.1002/jex2.119.


Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.

Sorino C, Mondoni M, Marchetti G, Agati S, Inchingolo R, Mei F J Clin Med. 2023; 12(22).

PMID: 38002620 PMC: 10672377. DOI: 10.3390/jcm12227006.


Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition.

Napoli F, Rapa I, Izzo S, Rigutto A, Libener R, Riganti C Virchows Arch. 2022; 481(2):233-244.

PMID: 35461395 PMC: 9343276. DOI: 10.1007/s00428-022-03321-8.


Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.

Schillebeeckx E, van Meerbeeck J, Lamote K Eur Respir Rev. 2021; 30(162).

PMID: 34789461 PMC: 9489015. DOI: 10.1183/16000617.0057-2021.


The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.

Lettieri S, Bortolotto C, Agustoni F, Lococo F, Lancia A, Comoli P J Clin Med. 2021; 10(5).

PMID: 33802313 PMC: 7959144. DOI: 10.3390/jcm10051034.


References
1.
Pass H, Lott D, Lonardo F, Harbut M, Liu Z, Tang N . Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353(15):1564-73. DOI: 10.1056/NEJMoa051185. View

2.
Cao X, Rodarte C, Zhang L, Morgan C, Littlejohn J, Smythe W . Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biol Ther. 2007; 6(2):246-52. DOI: 10.4161/cbt.6.2.3626. View

3.
Creaney J, Yeoman D, Naumoff L, Hof M, Segal A, Musk A . Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007; 62(7):569-76. PMC: 2117248. DOI: 10.1136/thx.2006.068114. View

4.
Grigoriu B, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P . Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007; 13(10):2928-35. DOI: 10.1158/1078-0432.CCR-06-2144. View

5.
Addis B, Roche H . Problems in mesothelioma diagnosis. Histopathology. 2008; 54(1):55-68. DOI: 10.1111/j.1365-2559.2008.03178.x. View